Hostname: page-component-586b7cd67f-tf8b9 Total loading time: 0 Render date: 2024-11-23T00:33:17.094Z Has data issue: false hasContentIssue false
  • English
  • Français

Life-threatening cardiac hypertrophy associated with dexamethasone treatment of bronchopulmonary dysplasia

Published online by Cambridge University Press:  19 August 2008

Keith J. Gallaher ,
Braxton Strickland ,
Kimberly Pickett  and
Jan M. Carter
Keith J. Gallaher*
Affiliation:
From the Division of Neonatology, Cape Fear Valley Medical Center, Fayetteville
Braxton Strickland
Affiliation:
Department of Nursing, Cape Fear Valley Medical Center, Fayetteville
Kimberly Pickett
Affiliation:
The Heart Center, Cape Fear Valley Medical Center, Fayetteville
Jan M. Carter
Affiliation:
From the Division of Neonatology, Cape Fear Valley Medical Center, Fayetteville
*
Dr. Keith J. Gallaher, Division of Neonatology, Cape Fear Valley Medical Center, P. O. Box 2000, Fayetteville, NC 28302USA. Tel. 910-609-6762; Fax. 910-433-7696.
Get access Rights & Permissions [Opens in a new window]

Summary

We report the case of an infant who developed severe cardiac compromise due to hypertrophic obstructive cardiomyopathy that developed while he was being treated with dexamethasone for bronchopulmonary dysplasia. This case is illustrative, as previous reports have described steroid-induced hypertrophic obstructive cardiomyopathy as being transient and benign. In this infant, the hypertrophic obstructive cardiomyopathy, waxed, waned, waxed, and waned again during two courses of dexamethasone, thus strengthening a causal link with steroid therapy. A high index of suspicion of hypertrophic obstructive cardiomyopathy as the etiology of hypoperfusion in steroid-treated infants with bronchopulmonary dysplasia is important. Serial echocardiographic monitoring of these infants is helpful in identifying cardiac compromise.

Keywords

Bronchopulmonary dysplasiahypertrophic obstructive cardiomyopathydexamethasone
Type
Brief Reports
Information
Cardiology in the Young , Volume 6 , Issue 4 , October 1996 , pp. 337 - 340
Copyright
Copyright © Cambridge University Press 1996

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.Collaborative Dexamethasone Trial Group. Dexamethasone therapy in neonatal chronic lung disease: An international placebo controlled trial. Pediatrics 1991; 88: 421–427.Google Scholar
2.Brand, PLP, van Lingen, RA, Brus, F, Talsma, MD, Elzenga, NJ. Hypetrophic obstructive cardiomyopathy as a side effect of dexamethasone treatment for bronchopulmonary dysplasia. Acta Pediatr 1993; 82: 614–617.CrossRefGoogle Scholar
3.Ohning, BL, Fyfe, DA, Riedel, PA. Reversible obstructive hypertrophic cardiomyopathy after dexamethasone therapy for bronchopulmonary dysplasia. Amer Heart J 1994; 125: 253–256.CrossRefGoogle Scholar
4.Werner, JC, Sicard, RE, Hansen, TWR, Solomon, E, Cowett, RM, Oh, W. Hypertrophic cardiomyopathy associated with dexamethasone therapy for bronchopulmonary dysplasia. J Pediatr 1992; 120: 286–291.CrossRefGoogle ScholarPubMed
5.Israel, BA, Sherman, FS, Guthrie, RD. Hypertrophic cardiomyopathy associated with dexamethasone therapy for chronic lung disease in preterm infants. Amer J Perinatology 1993; 10: 307–310.CrossRefGoogle ScholarPubMed
6.Maron, BJ. Cardiomyopathies. In: Adams, FH, Emmanouilides, GC (eds). Heart disease in Infants, Children, and Adolescents. Williams and Wilkins, Baltimore, 1983, pp 757–780.Google Scholar